227 related articles for article (PubMed ID: 25290828)
1. Challenges of Huntington's disease and quest for therapeutic biomarkers.
Kotrcova E; Jarkovska K; Valekova I; Zizkova M; Motlik J; Gadher SJ; Kovarova H
Proteomics Clin Appl; 2015 Feb; 9(1-2):147-58. PubMed ID: 25290828
[TBL] [Abstract][Full Text] [Related]
2. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
3. Proteomics of Huntington's disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances.
McQuade LR; Balachandran A; Scott HA; Khaira S; Baker MS; Schmidt U
J Proteome Res; 2014 Dec; 13(12):5648-59. PubMed ID: 25316320
[TBL] [Abstract][Full Text] [Related]
4. Huntington's disease: pathomechanism and therapeutic perspectives.
Gárdián G; Vécsei L
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1485-94. PubMed ID: 15480847
[TBL] [Abstract][Full Text] [Related]
5. Huntington's disease: new paths to pathogenesis.
Ross CA
Cell; 2004 Jul; 118(1):4-7. PubMed ID: 15242639
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
7. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
Tobore TO
J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.
Chen CM
Chang Gung Med J; 2011; 34(2):135-52. PubMed ID: 21539755
[TBL] [Abstract][Full Text] [Related]
9. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
Wanker EE
Biol Chem; 2000; 381(9-10):937-42. PubMed ID: 11076024
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G; Cha JH
Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and potential therapeutical targets in Huntington's disease.
Zuccato C; Valenza M; Cattaneo E
Physiol Rev; 2010 Jul; 90(3):905-81. PubMed ID: 20664076
[TBL] [Abstract][Full Text] [Related]
12. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
Essa MM; Moghadas M; Ba-Omar T; Walid Qoronfleh M; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Ray B; Bhat A; Chidambaram SB; Fernandes AJ; Song BJ; Akbar M
Neurotox Res; 2019 Apr; 35(3):739-774. PubMed ID: 30632085
[TBL] [Abstract][Full Text] [Related]
13. Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis.
Ratovitski T; Chighladze E; Arbez N; Boronina T; Herbrich S; Cole RN; Ross CA
Cell Cycle; 2012 May; 11(10):2006-21. PubMed ID: 22580459
[TBL] [Abstract][Full Text] [Related]
14. Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease.
Hands SL; Mason R; Sajjad MU; Giorgini F; Wyttenbach A
Biochem Soc Trans; 2010 Apr; 38(2):552-8. PubMed ID: 20298220
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.
Heiser V; Scherzinger E; Boeddrich A; Nordhoff E; Lurz R; Schugardt N; Lehrach H; Wanker EE
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6739-44. PubMed ID: 10829068
[TBL] [Abstract][Full Text] [Related]
16. Proteomic Analysis of Huntington's Disease.
Kumar S; Singh P; Sharma S; Ali J; Baboota S; Pottoo FH
Curr Protein Pept Sci; 2020; 21(12):1218-1222. PubMed ID: 33023443
[TBL] [Abstract][Full Text] [Related]
17. Mouse models of Huntington's disease and methodological considerations for therapeutic trials.
Ferrante RJ
Biochim Biophys Acta; 2009 Jun; 1792(6):506-20. PubMed ID: 19362590
[TBL] [Abstract][Full Text] [Related]
18. Update on Huntington's disease.
Berman SB; Greenamyre JT
Curr Neurol Neurosci Rep; 2006 Jul; 6(4):281-6. PubMed ID: 16822347
[TBL] [Abstract][Full Text] [Related]
19. Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains.
Sap KA; Guler AT; Bezstarosti K; Bury AE; Juenemann K; Demmers JA; Reits EA
Mol Cell Proteomics; 2019 Sep; 18(9):1705-1720. PubMed ID: 31138642
[TBL] [Abstract][Full Text] [Related]
20. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
Neo SH; Tang BL
Prog Mol Biol Transl Sci; 2018; 154():105-145. PubMed ID: 29413175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
